ZA969812B - Novel quinoline derivatives. - Google Patents

Novel quinoline derivatives.

Info

Publication number
ZA969812B
ZA969812B ZA9609812A ZA969812A ZA969812B ZA 969812 B ZA969812 B ZA 969812B ZA 9609812 A ZA9609812 A ZA 9609812A ZA 969812 A ZA969812 A ZA 969812A ZA 969812 B ZA969812 B ZA 969812B
Authority
ZA
South Africa
Prior art keywords
quinoline derivatives
novel quinoline
novel
derivatives
quinoline
Prior art date
Application number
ZA9609812A
Other languages
English (en)
Inventor
Carlo Farina
Giuseppe Giardina
Mario Grugni
Luca Francesco Raveglia
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of ZA969812B publication Critical patent/ZA969812B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9609812A 1995-11-24 1996-11-22 Novel quinoline derivatives. ZA969812B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds

Publications (1)

Publication Number Publication Date
ZA969812B true ZA969812B (en) 1998-05-22

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609812A ZA969812B (en) 1995-11-24 1996-11-22 Novel quinoline derivatives.

Country Status (23)

Country Link
US (3) US6355654B1 (xx)
EP (1) EP0876348B1 (xx)
JP (1) JP4377454B2 (xx)
KR (1) KR19990071599A (xx)
CN (1) CN1207728A (xx)
AR (1) AR004970A1 (xx)
AT (1) ATE233243T1 (xx)
AU (1) AU722451B2 (xx)
BR (1) BR9611729A (xx)
CA (1) CA2238312A1 (xx)
CZ (1) CZ158198A3 (xx)
DE (1) DE69626416T2 (xx)
ES (1) ES2192621T3 (xx)
GB (1) GB9524137D0 (xx)
HU (1) HUP9903584A3 (xx)
IL (1) IL124352A0 (xx)
MX (1) MX9804106A (xx)
NO (1) NO310866B1 (xx)
NZ (1) NZ323389A (xx)
PL (1) PL326927A1 (xx)
TR (1) TR199800925T2 (xx)
WO (1) WO1997019928A1 (xx)
ZA (1) ZA969812B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2000058313A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
JP2008542367A (ja) * 2005-06-03 2008-11-27 アストラゼネカ・アクチエボラーグ Ｎｋ−３アンタゴニストとしてのキノリン誘導体
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504572A (ja) * 2005-08-02 2009-02-05 スミスクライン・ビーチャム・コーポレイション キノリン誘導体の合成方法
US20080280949A1 (en) * 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
CN101268052A (zh) * 2005-09-21 2008-09-17 阿斯利康(瑞典)有限公司 作为nk-3受体配体的n-氧代-杂环和n-氧代-烷基喹啉-4-甲酰胺
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
WO2013066736A1 (en) 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204952T3 (es) * 1994-05-27 2004-05-01 Glaxosmithkline S.P.A. Derivados de la quinoleina utiles como antagonistas del receptor nk3 de la taquiquinina.
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
DE69626416D1 (de) 2003-04-03
PL326927A1 (en) 1998-11-09
US6355654B1 (en) 2002-03-12
NO982332L (no) 1998-05-22
JP2000500770A (ja) 2000-01-25
WO1997019928A1 (en) 1997-06-05
MX9804106A (es) 1998-09-30
GB9524137D0 (en) 1996-01-24
JP4377454B2 (ja) 2009-12-02
EP0876348A1 (en) 1998-11-11
US20020156097A1 (en) 2002-10-24
AU722451B2 (en) 2000-08-03
AU1031997A (en) 1997-06-19
CA2238312A1 (en) 1997-06-05
EP0876348B1 (en) 2003-02-26
TR199800925T2 (xx) 2001-05-21
HUP9903584A2 (hu) 2000-02-28
DE69626416T2 (de) 2003-12-24
US20020077335A1 (en) 2002-06-20
NO310866B1 (no) 2001-09-10
IL124352A0 (en) 1998-12-06
CN1207728A (zh) 1999-02-10
KR19990071599A (ko) 1999-09-27
ES2192621T3 (es) 2003-10-16
ATE233243T1 (de) 2003-03-15
BR9611729A (pt) 1999-04-06
NO982332D0 (no) 1998-05-22
US6432977B1 (en) 2002-08-13
NZ323389A (en) 2000-02-28
AR004970A1 (es) 1999-04-07
HUP9903584A3 (en) 2001-10-29
CZ158198A3 (cs) 1998-10-14

Similar Documents

Publication Publication Date Title
IL124522A0 (en) Quinoline derivatives
ZA961444B (en) Pyrazolylbenzoyl derivatives.
IL113844A0 (en) Quinoline derivatives
MX213417B (es) Fenilpiridazinonas.
ZA97521B (en) 19-Nor-pregnene derivatives.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
ZA961955B (en) Indazolecarboxamides.
ZA961697B (en) Indole derivatives.
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
HK1018457A1 (en) Alkylaminobenzothiazole and-benzoxazole derivatives.
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA969812B (en) Novel quinoline derivatives.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
GB9404378D0 (en) Quinoline derivatives
ZA966399B (en) Endothelin-receptor-antagonists.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA954269B (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
GB9413150D0 (en) Quinoline derivatives
ZA971167B (en) Heterocyclyl-ergoline derivatives.
CY2322B1 (en) Benzoaeguequinoline derivatives.